Table 2.
Comparison of clinicopathological features between bMF-ICC and pMF-ICC by subgroup analysis
| Tumor size ≤ 50 mm (n = 79) | Tumor size > 50 mm (n = 62) | |||||
|---|---|---|---|---|---|---|
| Clinical features | bMF-ICC (n = 18) | pMF-ICC (n = 61) | p-value | bMF-ICC (n = 15) | pMF-ICC (n = 47) | p-value |
| Age (years) | 63.67 ± 10.41 | 62.46 ± 10.89 | 0.68 | 58.20 ± 9.69 | 61.87 ± 9.18 | 0.19 |
| Sex (male/female, %) | 13 (72.2%)/5 (27.8%) | 43 (70.5%)/18 (29.5%) | 0.89 | 9 (60.0%)/6 (40.0%) | 18 (38.3%)/29 (61.7%) | 0.14 |
| Tumor markers | ||||||
| AFP ≥ 20 µg/La | 1 (5.6%) | 1 (1.7%) | 0.41 | 2 (14.3%) | 7 (15.6%) | 1.00 |
| AFP < 20 µg/L | 17 (94.4%) | 59 (98.3%) | 12 (85.7%) | 38 (84.4%) | ||
| CEA ≥ 5 µg/Lb | 6 (33.3%) | 11 (18.6%) | 0.32 | 8 (53.3%) | 10 (22.2%) | 0.051 |
| CEA < 5 µg/L | 12 (66.7%) | 48 (81.4%) | 7 (46.7%) | 35 (77.8%) | ||
| CA19-9 ≥ 34 µg/La | 8 (44.4%) | 18 (30.0%) | 0.25 | 6 (40.0%) | 16 (35.6%) | 0.76 |
| CA19-9 < 34 µg/L | 10 (55.6%) | 42 (70.0%) | 9 (60.0%) | 29 (64.4%) | ||
| HBsAg (+) (%)a | 4 (22.2%) | 26 (43.3%) | 0.11 | 7 (46.7%) | 11 (23.9%) | 0.18 |
| Cirrhosis (%)a | 0 | 10 (16.7%) | 0.15 | 1 (6.7%) | 2 (4.3%) | 1.00 |
| Leukocyte, median (IQR) (109) | 6.29 (4.95–7.66) | 5.34 (4.49–7.25) | 0.38 | 6.45 (5.71–7.05) | 6.39 (4.87–7.59) | 0.60 |
| Neutrophil, median (IQR) (*109) | 3.30 (2.90–4.50) | 3.20 (2.26–4.56) | 0.39 | 3.96 (3.50–4.90) | 4.00 (3.00–4.72) | 0.63 |
| Pathological classification, small/large duct type (%)a | 1 (5.9%)/16 (94.1%) | 49 (84.5%)/9 (15.5%) | < 0.001* | 6 (40.0%)/9 (60.0%) | 42 (93.3%)/3 (6.7%) | < 0.001* |
| Pathological gradinga | 0.78 | 1.00 | ||||
| G1 | 0 | 0 | 0 | 0 | ||
| G2 | 14 (77.8%) | 44 (74.6%) | 12 (80.0%) | 37 (78.7%) | ||
| G3 | 4 (22.2%) | 15 (25.4%) | 3 (20.0%) | 10 (21.3%) | ||
| Microvascular invasion (%) | 10 (55.6%) | 7 (11.5%) | < 0.001* | 8 (53.3%) | 4 (8.5%) | 0.001* |
| Multiple tumors (%)a | 1 (5.6%) | 8 (13.6%) | 0.77 | 7 (46.7%) | 5 (10.6%) | 0.007* |
| Perineural invasion (%)a | 3 (21.4%) | 20 (33.3%) | 0.59 | 10 (66.7%) | 13 (27.7%) | 0.006* |
| Lymph node metastasis (%) | 11 (61.1%) | 4 (6.6%) | < 0.001* | 5 (33.3%) | 2 (4.3%) | 0.009* |
| Bile duct invasion (%) | 9 (50.0%) | 3 (4.9%) | < 0.001* | 7 (46.7%) | 3 (6.4%) | 0.001* |
| Hepatic capsule invasion (%)a | 6 (46.2%) | 19 (34.5%) | 0.65 | 8 (61.5%) | 17 (36.2%) | 0.10 |
| Ki-67 (+)a (%)b | 10 (55.6%) | 24 (39.3%) | 0.22 | 11 (73.3%) | 18 (38.3%) | 0.02* |
IQR interquartile range, AFP alpha-fetoprotein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
* p-value < 0.05
a Serum AFP, CEA, CA19-9, HBsAg (+), cirrhosis, pathological grading, pathological classification, multiple tumors, perineural invasion, hepatic capsule invasion and Ki-67 have missing values in 4, 4, 3, 2, 1, 1, 6, 5, 5, 13 and 1 cases, respectively
b Ki-67 (+) indicates high Ki-67 expression